生物股份(600201) - 2018 Q1 - 季度财报

Financial Performance - In Q1 2018, the net profit attributable to shareholders, excluding non-recurring gains and losses, was CNY 319,661,200.79, representing a year-on-year increase of 21.37%[5] - The net profit attributable to shareholders for Q1 2018 was CNY 296,313,193.50, up 11.40% from the same period last year[6] - The basic earnings per share for Q1 2018 was CNY 0.35, an increase of 12.90% year-on-year[6] - The company's total comprehensive income for Q1 2018 was impacted by a loss in other comprehensive income of ¥42,756.52[34] - The net profit for Q1 2018 was ¥300,879,558.29, representing a 13.2% increase from ¥265,647,297.28 in Q1 2017[34] - The net profit for Q1 2018 was CNY 11,080,194.23, a significant recovery from a net loss of CNY 9,592,906.96 in Q1 2017[38] Revenue and Costs - Operating revenue for Q1 2018 was CNY 557,328,263.99, reflecting a growth of 20.92% year-on-year[6] - Operating revenue increased by 96.43 million yuan, a growth of 20.92%, primarily due to direct sales of foot-and-mouth disease vaccines and the addition of new subsidiary Liaoning Yikang's poultry products revenue[16] - Total operating revenue for Q1 2018 reached ¥557,328,263.99, an increase of 20.9% compared to ¥460,895,231.81 in the same period last year[33] - Total operating costs for Q1 2018 were ¥217,211,237.00, up 43.0% from ¥151,877,203.10 in Q1 2017[34] - Operating costs rose by 39.10 million yuan, an increase of 41.66%, mainly driven by the increased revenue from vaccines and poultry products, leading to corresponding cost increases[16] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,253,502,720.40, an increase of 10.03% compared to the end of the previous year[6] - Total assets as of March 31, 2018, amounted to ¥4,927,941,681.12, slightly down from ¥4,933,618,441.35 at the beginning of the year[30] - Total liabilities as of March 31, 2018, were ¥1,514,687,798.01, a decrease from ¥1,556,581,952.67 at the start of the year[31] - The company's equity attributable to shareholders reached ¥3,413,253,883.11, up from ¥3,377,036,488.68 at the beginning of the year[31] Cash Flow - Cash flow from operating activities for the period was CNY 58,538,667.06, a decline of 64.13% compared to the previous year[6] - Cash flow from operating activities generated a net amount of CNY 58,538,667.06, down from CNY 163,215,396.30 in the same quarter last year[40] - The company reported cash and cash equivalents at the end of the period amounting to CNY 2,205,726,854.32, a decrease from CNY 2,489,388,274.88 at the end of the previous year[41] - The ending balance of cash and cash equivalents was $1,576,065,578.03, down from $1,892,030,020.80 at the beginning of the period[44] - The company experienced a decrease in cash flow from operating activities, highlighting potential operational challenges[44] Investments - Investment income increased by 7.15 million yuan, a significant rise of 402.12%, primarily from increased returns on financial products[16] - The company reported an investment income of ¥8,927,522.85, significantly higher than ¥1,777,962.79 in the previous year[34] - Investment activities resulted in a net cash outflow of CNY 71,067,169.31, slightly improved from a net outflow of CNY 74,479,471.33 in the previous year[41] - Total cash inflow from investment activities amounted to $326,049,753.43, up from $212,455,345.21 year-over-year[44] - Cash outflow from investment activities reached $633,502,303.19, compared to $309,004,000.00 in the prior period, resulting in a net cash flow from investment activities of -$307,452,549.76[44] Shareholder Information - The total number of shareholders at the end of the reporting period was 23,022[11] - The company incurred share-based payment expenses of CNY 25,137,200.00 related to the restricted stock incentive plan during the reporting period[5]